Cancer drugs - A pratical approach to drugs available to us

What do doxorubicin and adriamycin have in common? Why can the indications for platinum compounds vary so much? Have monoclonal antibodies ousted cytotoxic drugs? What is an anticancer antibiotic? The aim of this book is to answer these questions, and all those that arise from being in contact with cancer drugs. To do this, we first need to classify each one in relation to the others. Each product is then described, detailing its official indications, as validated by its marketing license, then its dose, its mode of administration and the precautions that need to be taken when using it, any eventual resistance it may generate, and finally, the side effects it may cause.